<DOC>
	<DOCNO>NCT01124123</DOCNO>
	<brief_summary>The purpose study ass absolute bioavailability oral bilastine formulation ( test drug ) compare endovenous administration IV bilastine formulation ( control drug ) healthy volunteer .</brief_summary>
	<brief_title>Oral Bioavailability Bilastine</brief_title>
	<detailed_description>Single centre , open label , cross-over , randomise , control , single dose study . The primary endpoint determination plasma concentration versus time ( 17 sample per subject various time interval dose ) order assess oral bioavailability bilastine healthy volunteer . Therefore primary pharmacokinetic variable area plasma concentration versus time curve time zero infinity ( AUC 0-∞ ) . Additionally follow pharmacokinetic variable also assess : Cmax , AUC 0-t , tmax , Ae , Clr , t1/2 . Additional objective describe safety tolerability single administration oral endovenous bilastine healthy volunteer . Twelve healthy volunteer include . Each volunteer take random order one single dose 20 mg oral bilastine 10 mg IV bilastine minimum washout period 14 day . Bilastine plasma concentration measure use liquid chromatography/mass mass spectrometry ( LC/MS/MS ) micro method</detailed_description>
	<criteria>Healthy volunteer either sex age ≥ 18 ≤ 35 year age . Body mass index 19 29 Kg/m2 . Non smoker . Judged general good health base medical history , physical examination clinical laboratory test . Able communicate well investigator comply requirement entire study . Provision write informed consent participate . Pregnant breastfeed woman positive pregnancy test . Subjects agree use adequate method contraception study . Intake another investigational medication another clinical study within 4 month prior first study drug intake . Regular use prescribed medication include medicinal herbs OTC medication within 4 week dose . A QTc &gt; 430 m male QTc &gt; 450 m female . A HR &lt; 55 bpm . Existence surgical medical condition , judgement investigator , might interfere absorption , distribution , metabolism excretion IMP . Known allergy/hypersensitivity study drug inactive ingredient . Any clinical condition circumstance opinion investigator would make subject unsuitable study ( e.g. , hepatic impairment , renal impairment , mental impairment , cardiac disease ) . Presence hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV Ab ) HIV 1 HIV 2 antibody screen . Subjects take metabolic transporter inducers/inhibitors 3 month prior inclusion study . Donation loss great 200 mL blood within 12 week entry study . Blood transfusion within prior 6 month inclusion . Ingestion citrus fruit cranberry fruit juice within 7 day prior first dose study medication . Known current alcohol drug abuse . Excessive consumption xanthine contain food drink . Mentally disabled subject subject official order institutionalise must exclude participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Oral bioavailability</keyword>
	<keyword>absorption</keyword>
	<keyword>AUC</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Bioavailability study</keyword>
</DOC>